Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

NCT04503668 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

62

Enrollment

OTHER

Sponsor class

Stopped Lack of Patient Population

Conditions

Gynecologic Cancer

Interventions

DRUG: Ondansetron
DRUG: Dexamethasone
DRUG: Neurokinin-1 Receptor Antagonist (NK1-RA)
DRUG: Olanzapine
DRUG: Compazine

Sponsor

University of Michigan Rogel Cancer Center